Sangamo Therapeutics Faces Critical Survival Test as Shares Plunge

Sangamo Therapeutics finds itself navigating perilous financial waters, with its stock experiencing a dramatic 21% decline following disappointing quarterly results and mounting liquidity concerns. The biotech firm now confronts fundamental challenges that threaten its continued existence.

The company’s stock market listing hangs in the balance after Nasdaq granted a 180-day grace period. Sangamo must elevate its share price above the critical $1 threshold by April 27, 2026, or face potential delisting—a devastating scenario for investors. Market reaction has been severe, with shares dropping to $0.46 on November 6 before declining an additional 21.1% by November 9.

Quarterly Performance Reveals Deep Troubles

The third quarter of 2025 proved disastrous for the biotechnology company. Revenue collapsed to Read more...